Kalbe Announced Dividend of 51.5% from Net Profit

Dari Kiri ke Kanan: Mulialie, Sie Djohan, Vidjongtius, Bernadette Ruth Irawati Setiady, Lilis Halim, Bernadus Karmin Winata, Jos Iwan Atmadjaja

No. 034/KFCP-DIR/PR/V/22

Jakarta, May 19, 2022- PT Kalbe Farma Tbk ("Kalbe" or "the Company")willdistribute cash dividend of Rp35per share. The distribution of cash dividendhas been approved by the Shareholders of the Company in the Annual General Meeting of Shareholders ("AGMS") held in Gedung Kalbe Business Innovation Center, Pulogadung, Jakarta.In compliance with the prevailing regulations, dividend payment will be made at the latest within 30 days after the announcement of AGMS where the Company will shortly announce the schedule and procedures.

In an increasingly challenging of global macroeconomic conditions and supply chains, the Company continues to strengthen the supply of raw materials to maintain product availability. The Company also maintains a strong liquidity position to anticipate future working capital needs. Innovation continues to be carried out in order to provide products and services that are in line with the needs of the community and to support sales growth.

In 2022, the Company remains optimistic about the potential for growth and projects a sales and net profit increase of 11-15%. The capital expenditure allocation is budgeted at Rp1 trillion to increase the production capacity and distribution network of the Company. The expenditure budget will also be used for the maintenance and completion of the previous year's project. Taking into account cash flow and the need for operational and investment funds, the Company will maintain a policy of distributing dividends of around 45-55% of net income. The Company has also completed a share buyback program with a total value of Rp 400.2 billion for the period 09 February - 08 May 2022.

In the AGMS, the Company has also obtained the approval of the shareholders on the following agenda:

1. Approval of the Annual Report of the Company for the year ended
December 31, 2021, including the Activity Report of the Company, the Report of the Supervisory Role of the Board of Commissioners, approval and ratification of the Company's Audited Financial Statements for the year ended December 31, 2021and to grant a release and discharge from their responsibilities to all members of the Board of Commissioners and Board of Directors for their management and supervision actions during the financial year ended December 31, 2021(acquit et de charge);

2. Approval on the appropriation of the Company's Net Profits for the financial year ended December 31, 2021;

3. Appointment of the Company's Board of Directors and Board of Commissioners as follows until the end of terms in 2023:

Board of Commisioners:

President Commissioner : BERNADETTE RUTH IRAWATI SETIADY;

Commissioner : SANTOSO OEN;

Commissioner : FERDINAND ARYANTO;

Commissioner : RONNY HADIANA;

Independent Commissioner :

LILIS HALIM;

Independent Commissioner :

ADI HARSONO;

Independent Commissioner :

RHENALD KASALI;

Directors:

PresidentDirector : VIDJONGTIUS;

Director: BERNADUS KARMIN WINATA;

Director : SIE DJOHAN;

Direktur : MULIALIE;

Direktur : JOS IWAN ATMADJAJA

4. Determination of the salary and/or honorarium of the members of theCompany's Board of Commissioners and members of the Board of Directors and to authorize the Board of Commissioners to determine the salary and/or honorarium of the members of the Board of Directors, by considering the recommendation from the Nomination and Remuneration Committee;

5. Authorization to the Board of Commissioners to appoint a Registered Public Accountant Firm (including Public Accountants who are members of the Registered Public Accounting Firm) to audit the Company's Financial Statements for the financial year ended on the December 31, 2022, by granting authority to the Board of Directors of the Company to determine the honorarium for the Independent Public Accountant and other requirements for its appointment, taking into account the recommendations of the Audit Committee.

Kalbe at a Glance

PT Kalbe Farma Tbk. ("Kalbe") was established in 1966 and is one of the largest publicly-listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions managing a broad and strong portfolio of brands; Prescription Pharmaceuticals Division, Consumer Health Division comprising over-the-counter drugs, as well as supplementdrink and ready to drink products, Nutritionals Division, and Distribution & Logistics Division. Kalbe currently has more than 40 subsidiaries and 15production facilities with international standards employed around 16,000 employees and have 76 branches of distribution & logistics across Indonesia. Since 1991, Kalbe's shares have been listed on the Indonesia Stock Exchange (IDX: KLBF).

Print

24Rate this article:

Please login or register to post comments.